Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | CPA1 | P15085 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 11/20 | 0.39 |
| ▸ | MMP9 | P14780 | 2/20 | 0.38 |
| ▸ | MMP8 | P22894 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5833229 | 0.89 | MAOB (0.42) | MMEACECPA1ACE2CACNA1B | |
| SCHEMBL5832747 | 0.88 | PSMB5 (0.42) | MMEACECPA1ACE2CACNA1B | |
| SCHEMBL5833023 | 0.88 | GPR132 (0.44) | MMEACECPA1ACE2CACNA1B | |
| SCHEMBL5833180 | 0.88 | CACNA1B (0.50) | MMEACECPA1ACE2CACNA1B | |
| SCHEMBL5833276 | 0.85 | TACR2 (0.44) | CACNA1BPSMB5REN | |
| SCHEMBL5833073 | 0.82 | MME (0.45) | MMEACECPA1ACE2CACNA1B | |
| SCHEMBL5833633 | 0.78 | MME (0.44) | MMEACECPA1ACE2CACNA1B | |
| SCHEMBL5833273 | 0.78 | GPR132 (0.44) | MMEACECPA1ACE2CACNA1B | |
| SCHEMBL5833508 | 0.76 | CACNA1B (0.52) | MMEACECPA1ACE2CACNA1B | |
| SCHEMBL5833821 | 0.76 | MME (0.46) | MMEACECPA1ACE2CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030060419-A1 | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers | HU LAIN-YEN (US) | 2003-03-27 | — | — | US | claimed |
| US-6989448-B2 | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers | HU LAIN-YEN | 2006-01-24 | — | — | US | disclosed |
| US-20030060419-A1 | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers | HU LAIN-YEN (US) | 2003-03-27 | — | — | US | disclosed |
| US-6469038-B1 | CALCIUM CHANNEL BLOCKERS THAT CAN BLOCK N-TYPE CALCIUM CHANNELS AND CAN BE USED TO TREAT STROKE, PAIN, CEREBRAL ISCHEMIA, HEAD TRAUMA, ASTHMA, AMYOTROPIC LATERAL SCLEROSIS, AND EPILEPSY | WARNER-LAMBERT COMPANY | 2002-10-22 | — | — | US | disclosed |
| US-6166052-A | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers | WARNER-LAMBERT COMPANY (US) | 2000-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060419-A1 | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers | CACNA1C, CACNA1I, CACNA1S | MME 2301/4885ACE 2025/4885CPA1 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.